Jonas A. de Souza - Concepedia

Author

Jonas A. de Souza

Also Known As

Hayes, D.N., J A Souza, J A de Souza, J. A. De Souza, J. A. de Souza, J.A. De Souza, J.A. de Souza, Jonas A De Souza, Jonas A de Souza, Jonas A. De Souza

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

University of Chicago The University of Texas MD Anderson Cancer Center University of Chicago Medical Center Northwestern University Chicago Department of Public Health

About

Jonas A. de Souza is an author at University of Chicago specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	19	1.5K
2	Health Sciences	7	7	1.1K
3	Business	1	1	55
4	Management	1	1	54
5	Natural Sciences	1	1	11

Jonas A. de Souza

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) Jonas A. de Souza, Bonnie J. Yap, Kristen Wroblewski, Cancer Quality Of LifeCancer ManagementClinical EndpointComprehensive ScoreBackground Cancer	2016	819
The development of a financial toxicity patient‐reported outcome in cancer: The COST measure Jonas A. de Souza, Bonnie J. Yap, Fay J. Hlubocky, Cancer	2014	607
Thyroid Cancer: Burden of Illness and Management of Disease Rebecca Brown, Jonas A. de Souza, Ezra E.W. Cohen Journal of Cancer	2011	187
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial Maria E. Cabanillas, Jonas A. de Souza, Susan M. Geyer, Journal of Clinical Oncology Oral Multikinase InhibitorsOncologyMedicineThyroid DiseasePathology	2017	128
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Jonas A. de Souza, Darren W. Davis, Yujian Zhang, Clinical Cancer Research	2012	113
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer Victoria Villaflor, J.M. Melotek, Theodore Karrison, Annals of Oncology Advanced HeadResponse-adapted Volume De-escalationNeck CancerRadiation TherapyMedicine	2016	95
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. Manisha H. Shah, Lai Wei, Lori J. Wirth, Journal of Clinical Oncology Dabrafenib Versus DabrafenibMedicineBraf MutationsThyroid DiseasePharmacology	2017	84
Determinants of Patient-Centered Financial Stress in Patients With Locally Advanced Head and Neck Cancer Jonas A. de Souza, Sunny Kung, Jeremy O’Connor, Journal of Oncology Practice	2017	58
Phase II trial of sunitinib in medullary thyroid cancer (MTC). Jonas A. de Souza, NL Busaidy, Ann B. Zimrin, Journal of Clinical Oncology Surgical OncologyPathologyNeuro-oncologyOncologyMtc Pts	2010	55
Validation of a financial toxicity (FT) grading system. Jonas A. de Souza, Kristen Wroblewski, Ellie Proussaloglou, Journal of Clinical Oncology PrognosisLogistic AnalysisFinancial ToxicityRisk ManagementClinical Epidemiology	2017	55

Page 1